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HUMAN LEUCOCYTE TYPING IN CLINICAL TRANSPLANTATION*
M. c. BOTHA, M.B., CH.B. (CAPE Tow) D.C.P. (LaND.), F.e. PATH. AND E. D. D TOIT, M.B., CH.B. (CAPE ToWN),
Provincial Blood Grouping Laboratory, Cape Town
At the out et two firm statements can be made: firstly,
there is now convincing proof that human leucocyte anti-
gens are transplantation antigens which are capable of
influencing the function and survival of kidney trans-
plant; secondly, it is becoming almost universally accept-
ed tbat matching of donor and recipient in terms of their
leucocyte antigens is desirable. There is, however, un-
certainty in many quarters as to just how desirable, or
necessary, prospective leucocyte antigen typing is in clinical
practice; and if it is done, to what extent it must be taken
into con ideration before embarking on a transplant.
The current value of leucocyte typing in transplantation
practice is best assessed by reviewing the accumulated
evidence which established a correlation between the de-
gree of leucocyte antigen matching of donor-recipient
pairs and the outcome of their renal transplants. When
doing so, it is as well to bear in mind the many reserva-
tions expressed in these reports by the investigators them-
selves. Problems arose from the fact that neither of the
two variables under examination, i.e. the degree of rejec-
tion and the degree of histocompatibility, was easy to
measure. Clinical assessment of the uccess of tran planta-
'Paper presented at the 47th South African Medical Congres (M.A.S.A.l,
Pretoria. July 1969.
tion was often unsatisfactory. Rejection was difficult to
recognize in the presence of post-tran plantation surgical
and medical complications; there were differences in im-
munosuppressive treatment from patient to patient, and
between group of patient; and differing criteria could
be and were applied to judge failure of a kidney tran -
plant. On the other hand, the econd variable, i.e. what
con titute a matched donor-recipient pair, was also diffi-
cult to define. Initially there was uncertainty because the
antisera which were used were admittedly unsatisfactory
a regard specificity and reproducibility of results; and it
was recognized that current methods of typing were al-
most certainly not capable of distinguishing all the tran -
plantation antigens. An important criticism of the earlier
studies which were based on retrospective leucocyte typing
of live donors and recipients was exclusion of those re-
cipients who had died.
LEUCOCYTE ANTIGEN MATCHI G AND THE RES LTS OF
KID EY TRA SPLANT
Table I ummarizes most of the experience of the past 5
year of leucocyte antigen matching and kidney tran-
plant .1." Studies dealing mainly with related donors
should be regarded separately from those which are con-
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episode with certainty, particularly in the early postopera-
tive period. Histological examination of the graft provides
a more objective and certain means of determining the
occurrence and severity of rejection. Furthermore, post-
mortem material and biopsy specimens may be combined
to provide an entire series. The histological grading of
Porter et al." has been widely adopted and has proved
very useful. The main features which are taken into ac-
count are the following:
I. Fibrous thickening of the intima of interlobular
arteries.
2. Hyalinization of the walls of the arterioles.
3. Thickening of the glomerular capillary basement
membranes.
4. Generalized interstitial fibrosis.
5. Superficial subcapsular interstitial fibrosis.
6. Cellular fibrosis.
7. Tubular atrophy.
Each lesion is scored from 1 to 3 for severity and then
scores are totalled for each kidney. Possible scores range
from 0 to 21.
Differences in clinical results were analysed in terms of
degrees of correspondence between the leucocyte antigens
of donor and recipient. The degree of leucocyte antigen
matching has also been expres ed in several ways. Several
terms have been used, quite often synonymously. 'Mis-
matched' is sometim~s used to imply incompatibility, i.e.
the donor possesses an antigen which is lacking in the
recipient; at other times 'mismatched' implies lack of
identity but compatibility, i.e. the donor is lacking an anti-
gen which is present in the recipient; this latter situation
is sometimes described by the term 'reverse mismatch';
'matched' may be used to imply 'identity', i.e. donor and
recipient agree in respect of every antiserum which is
used; however, in some studies 'matched' means no more
than that there is no direct incompatibility from donor to
recipient, but still permits the recipient to react positively
with certain antisera to which the donor is negative.
The confusion which may arise from untidy semantics is
bad enough. Even more confusing has been the use of
several different nomenclatures to designate leucocyte
antigens; and the number of antigens which were detected
by different serological techniques used in several centres
varied considerably from centre to centre, and within one
centre from time to time.
Less ambiguous definitions for classifying the degree of
leucocyte antigen matching have been introduced recently.
As examples, the terms used by Terasaki and by Van
Rood respectively are given in Tables III and IV.
Leucocyte serology made a very significant advance
when it was shown at the 1967 Workshop in Turin'" that
many independent workers using a variety of serological
methods were recognizing equivalent or closely related
antigens (Table V). Furthermore, penetrating family
studies such as those performed by Kissmeyer-Nielsen
et al. 19.'. and Dausset and Rapaport" have revealed the
distribution of antigens of narrow specificity at either of
two sub-loci of the HL-A system'" of leucocyte groups
(Table VI). In these term, an individual could possess a
2. Rejection
Type A
TABLE H. THE CLll'.'lCAL RANKING OF KIDNEY TRANSPLANT RECIPTENTS
(AFTER LEE et al.)"
1. Renal Function·
Grade A BU T less than 20 mg./l00 m1.
ECC over 70 m1./min.
BP normal
Grade B BUN 2G-40 mg./lOO m1.
ECC 70-40 ml./min.
BP diastolic(over 110 mm.Hg)controlled without
medication
Grade C B 40-100 mg.fl00 m!.
ECC 40-20 m1./min.
BP hypertension (over 110 mm.Hg) controlled
with medication
Grade D BUN over 100 mg./l00 m\.
ECC less than 20 m1./min.
BP hypertension difficult to control
cerned mainly with unrelated donors. Such distinction on
the basis of the genetic class of the donor is of con-
siderable importance in considering the immunogenetic
theory of leucocyte antigen matching; and the greater
degree of success which has been obtained in practice with
related-donor transplants has long been recognized clini-
cally.
In these studies several criteria have been used for as-
sessing the results of kidney transplants. These have in-
cluded survival of the patient, survival of the graft, the
clinical condition of the surviving patient and the histo-
logy of the transplanted organ. Among these measures of
success or failure, the clinical status of the surviving re-
cipient has proved the most difficult. In order to achieve
acceptable clinical comparison between recipients in a
series, it has been necessary to base the clinical ranking
on several parameters. Among the proposals for establish-
ing several clinical ranks, the formula which was used by
Lee et al." from Richmond, Virginia, has been adopted in
other centres. As an example of a clinical approach the
outlines of this scheme are given in Table II. Renal func-
tion is judged on blood urea nitrogen levels, endogenous
creatinine clearance and blood pressure; rejection is
graded according to the onset, number and severity of
separate episodes observed clinically. The clinical status
of each patient is finally determined by a synthesis of
renal function and rejection.
The function of a transplanted kidney may be affected
by medical and sur~ical complications other than rejec-
tion; and it is commonly difficult to diagnose a rejection
o rejection in first 4 months
o ignificant protein loss in urine
One rejection episode in first 4 months
Multiple rejection episodes in first 4 months
Any rejection episode after first 4 months
(I) Rejection in the first week
(2) Rejection lasting longer than 30 days
(3) Rejection episode requiring nephrectomy
3. Clinical Ranks








Fair to poor general health
Rank D Kidney has rejected
-BU = blood urea nitrogen; EeC = endogenous creatinine clearance;
BP = blood pressure.
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maximum of 4 antigens in the HL-A system. It is to be
noted, however, that evidence for the possibility of a third
sub-locus has been presented;'" this would raise the possi-
ble maximum to 6 antigens per individual. As the im-
munogenetics of the leucocyte antigens are becoming in-
creasingly clear, the possibility of accurately analysing the
degree of correspondence between a donor and recipient
also increases.
ot ideBtical 2-3




REPRESENTATIVE EXAMPLES OF CORRELATION STUDIES
Although some uncertainty has admittedly existed in
measuring clinical success as well as in defining leucocyte
antigen matching, the majority of studies concluded that
the closer the degree of matching the better the outcome
of the kidney transplant. The statistical correlation has
become progressively stronger in more recent analyses;
this is undoubtedly due to a combination of more success-
ful management of clinical complications other than re-
jection, and increasing accuracy of leucocyte typing
methods.
Several important points which must be considered III
determining the importance of leucocyte antigen matching
in human organ transplantation emerged from the reports
listed in Table I. For the purpose of discussion, a number
of illustrative tables have been reproduced or prepared
from those reports.
The pioneer studies of Terasaki et al.'" showed that a
closer degree of matching was correlated with improved
results in several directions; recipient~ who had been better
matched with their donors had less evident rejection, were
in better clinical condition and had a greater chance of
survival (Tables VII - IX). Payne et al." using a different
technique of determining leucocyte antigens, confirmed
the observation that recipients with matched correlated
donors were in better clinical condition than those patients
whose related donors were not well matched; the re-
cipients were assessed clinically according to Lee et al.'
(Table II). Using the same clinical classification, but yet
another serological technique, Dausset and Rapaport"
found a strong statistical correlation between compatibility
and a reduced evidence of rejection and longer survival
of the recipient (Table X). Whereas the conclusion had
TABLE IV. TERMS USED BY VAN ROOD
Meaning
Leucocyte groups of donor and recipient
are identical for the HL-A antigens
Leucocyte groups of donor and recipient
are identical for the HL-A antigens,
except for one antigen
Leucocyte groups of donor and recipient
are different for 2 to 3 of the HL-A
antigens
Leucocyte groups of donor and recipient
are different for 4 or more of the HL-A
antigens






Matched D to R (mismatched R to D)
B+ = R-D mismatched in 1 group
B = R-D mismatched in 2 groups
B- = R-D mismatched in 3 or more groups
Mismatched D to R in I group
C = R to D further mismatched in 0-2
groups
C- = R to D further mi~matched in 3 or
more groups
Mismatched D to R in 2 groups
D = R to D further mismatched in 0-2
groups
D- = R to D further mismatched in 3 or
more groups
Positive crossmatch: R serum reacts positively







TABLE V. HL-A NOMENCLATURE AND PREVIOUS DESIGNATIONS'" 28
New HL-A Kissmeyer- Payne/
nomenclature Amos Batchelor Ceppe//ini Da/lsset Nielsen Bodmer Van Rood Shulman Terasaki Walford
HL-AI 19 I To-8 11 LAl LAl I Le-I
HL-A2 I 5 To-9 I LA2]Ba LA2 8a PIGrLyBl 2 Lc-2
or Mac
HL-A3 4 To-lO 12 LA3]ILN LA3 Hill 8 Lc-3
HL-A4 [4a]
HL-A5 45 25 To-5 5 MH 6
HL-A6 [4b]
HL-A7 2 To-20 10 KN4B 4d 7c 5 Lc-8
HL-A8 41 2 To-7 8 7d 7d 11 Lc-?
HL-A4 will be reserved for one oflhe higher frequency 4a faclors, and HL-A6 for 4b •
TABLE VI. ANTIGENS ALLOCATED TO THE TWO MAIN SUB-LOCI OF THE HL-A SYSTEM ACCORDING TO DAUSSET A D KISSMEYER- 'IELSEN RESPECTIVELY
Kissmeyer-Nielsen
LAl, LA2. LA3. LA4. (NIH). Ba. ILN
T12, MH, 7e, 7d. 4c(payne). HN, BB
Two alleles controlling the







LAI (= 11), LA2 (= I), LA3 (= 12),15,16,17,
4, 5, 10, 8
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TABLE VIn. CORRELATION BETWEEN MISMATCHED LEUCOCYTE GROUPS
AND HISTOLOGICAL EVIDENCE Of REJECTION r ' KIDNEYS SURVIVI G
2 YEARS AFTER TRA SPLANT (AFTER TERASAKI et al.)"
Rejection
TABLE VB. CORRELATIO BETWEE UMBER OF MISMATCHED LEUCO-
CYTE GROUPS A D CLI ICAL GRADES OF 36 KID 'EY RECIPIENTS
SURVlVING 2 YEARS (AFTER TERASAKI et al.)'
umber of mismatched groups
Clinical
grade Nil One TlI'o
1 10 3 1
2 5 5 1
3 0 4 4

















the donor-recipient pair were exclusively or mainly re-
lated, the clinical material under analysis was not geneti-
cally homogenous. It was known from the earlier days of
kidney transplantation that the genetic relation hip be-
tween donor and recipient had in itself a significant effect
in survival. Fig. l, which i redrawn from the pre entation
of the Boston Kidney Transplantation Registry data by
Ceppellini et al.,'" illustrates the post-transplant course of
recipients divided according to the genetic relationship of
their donor. The genetic explanation for this variation wa








been made in some of the earlier studies that the bene-
ficial effect of leucocyte matching only became evident
among long-term survivors, Dausset's study revealed that
proved leucocyte compatibility also had an effect in re-
ducing the number and everity of early rejection episode
(Table XI).
Among the critici m levelled at these earlier studies wa




TABLE IX. CORRELATION BETWEEN LEUCOCYTE GROUP 1ATCHI 'G A '0
SURVIVAL Of PATIE TS WITH RENAL ALLOGRAFTS (AFTER TERASAKI
et al.)"
Fig. J. Different survival curves for several classe of
related donor kidney transplants and unrelated donor
kidney transplants before 1966.
TABLE X. LEUCOCYTE GROUP COMPATmlLITY CORRELATED WITH
REJECI'IO OR SURVrvAL OF RENAL TRANSPLA 'TS (RELATED DONORS)






TABLE XII. RELATIONSHIP BETWEE GE OTYPES OF PARENTS A D
THE DIFFERENCE IN DEGREE OF HISTOCOMPATIBILITY FOR THE

















I, I ; I, 2; Sib-to-Sib
Parent-to-Child
2,3; 2, 4. Parent-to-Child
1,1; 1,3; Sib-to-Sib






Both heterozygous; I, 2
x
no common allele 3, 4
Both heterozygous; I, 2
x
one common allele I, 3
One homozygous; t, 1
x
no common allele 2, 3
One homozygous; I, I
x

















TABLE XI. LEUCOCYTE GROUP COMPATmrLITY CORRELATED WITH
SEVERITY Of EARLY REJECTIO CRISES IN 14 SrBLlNG TRA SPLANTS












In order to allow for the influence of this variable in their
analysis, Van Rood et al.,,-n separated sibling-to-sibling
transplants from parent-to-child transplants, and in both
genetic classes compared matching with the 2-year survival
of the recipients (Tables XlII and XIV). It appeared from
this study that identity or near identity (no more than
one antigen differing between donor and recipient), for the
9 antigens of Van Rood's group 4 system, was the
only situation which improved the survival. Compatibility
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alone, i.e. a situation where the donor lacked antigen~
which were present in the recipient, was not associated'
with better re~ults than were incompatibilities. Identical
matching was statistically associated with survival in the
sibling-to-sibling transplants; the correlation was not
statistically significant in the parent-child combinations in
TABLE XIII. KIDNEY GRAFT SURVIVAL AND HL-A ANTIGENS (SIB-TO-SIB)
(AFTER VA ' ROOD et al.)'6
et al." In a series of sibling transplants a very clear cor-
relation between leucocyte antigen matching and the clini-
cal outcome was observed. In contrast. very little dif-
ference was seen between matched and mismatched donor-
recipient pairs in parent-to-child transplants (Figs. 2 and 3).
In considering this discrepancy, it was suggested that dif-
ferent degrees of compatibility, which would be expected


























TABLE XVI. CORRELATION BETWEEN DEGREE OF LEUCOCYTE MATCHING
AND CLINICAL STATUS, I 17 RELATED DONOR-RECIPIENT PAIRS
(AFTER KISSMEYER- IELSEN et al.)'9
Sib Parent Clinical rank ~
10 to
Matching grade sib child / 11 11/ /v
Identical antigens 8 1 9
One 0 to R incompatibility 4 2 "L
Two D to R incompatibili-
ties 2 2 2 2
p = > ·002
TABLE XIV. KID EY GRAFT SURVIVAL AND HL-A A TIGENS (PARENT-TO-
CHILD) (AFTER VAN ROOD et al.)'6
TABLE XV. CORREI.ATION BETWEEN IDENTITY FOR LEUCOCYTE ANTI-
GENS AND SURVIVAL OF SIB-TO-SIB KID EY GRAFT RECIPIENTS (AFTER






Identical 10·4 4·7 10

















































this series. These observations persuaded Van Rood and
Eeroisse" to classify as well-matched only related donor-
recipient pairs which were identical, or nearly so (Table
XV). Kissmeyer-Nielsen et al.'· provided clear confirma-
tion of the importance of identity or near-identity in
family donor transplants. In Table XVI it can be seen
that such a degree of leucocyte antigen matching was
consistently associated with recipients in better clinical
ranks; whereas incompatibility for two of Kissmeyer-
ielsen's antigens was associated with an inferior clinical
condition.
The difference in the degree of correlation between
matching and clinical outcome as observed in sibling-to-
sibling transplants compared with parent-to-child trans-
plants has recently been further emphasized by Singal
o 4 8 12 16 2024 28 32 3640 44 48
SURVIVAL TIME - MONTHS
SIB-YO-SIB
Fig. 2. Highly significant statistical correlation between
. leucocyte antigen matching and survival in sibling kidney
transplants (adapted from Singal et {d.).'·
In our opinion the genetic basis for these observations
can be easily illustrated; and the survival curves of- sib-
ling-to-sibling transplants can then be tentatively redrawn
to provide a particularly good illustration of the role of
leucocyte antigens in determining the success or otherwise
of kidney transplants,
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Because of the relatively large number of leucocyte anti-
gens at each of two sub-loci, many different alleles are
found in the general population. (In leucocyte immuno-
genetics, an allele at present represents a permanent coup-
ling of two genes on one chromosome. Ceppellini has
introduced the very useful term 'haplotype' to designate
transplants represent the sum of the identical transplants
plus most of the transplants carrying the lesser incompati-
bilities which may be associated with a one-allele dif-
ference between donor and recipient; while the lower
curve for mismatched sibling pairs represents tbe trans-
plants of two-allele differences, plus that proportion of
one-allele-differing transplants which carry the less
































POSSIBLE TRANSPLANTS WITHIN THE FAMILY










Fig. 4. The probabilities of obtaining various degr~es of
histocompatibility in random transplants between members
of a family in which the parents are heterozygous without
an allele or antigen in common.
PARENT - TO - CHILD
Fig. 3. Lack of high significant statistical correlation
between leucocyte antigen matching and survival in






coupled antigens which segregate together in a family.)
It is therefore common to find that both parents are
heterozygous, i.e. each possesses two differing haplotypes
or alleles. The varying probabilities of obtaining different
degrees of histocompatibility in unselected parent-ta-child
and sibling-to-sibling transplants in this type of family is
deduced from Fig. 4. In such a situation a transplant from
either parent to any child must of necessity carry one
different. or incompatible, allele. The distribution of these
4 parental alleles among the offspring determines that a
random transplant between any two siblings.. will stand a
50"" chance of being incompatible for one allele, i.e. the
same degree of incompatibility which follows from
parent-ta-child transplants; however, every fourth
random transplant from sibling-ta-sibling will be identical,
i.e. both the alleles will be matched; and by the same
token every fourth transplant will be incompatible for two
allele.
With reference to Fig. 2. we should like to suggest that
the upper survi al curve for matched sibling-to- ibling
favourable degrees of incompatibility which may be as-
sociated with one-allele differences. On theoretical grounds
survival curves for the 500 0 of sibling transplants which
are different for one allele would occupy more or less
the same position as that occupied by the curve of parent-
to-child transplants in Fig. 3; in theory the completely
identical transplants, if analysed separately, may then fol-
low an even higher curve than that plotted by Terasaki
for matched sibling-to- ibling transplants, while the 25 0 0
of transplants involving differences for both alleles may
show a much steeper decline in survival if regarded
separately. Tilis hypothesis is illustrated in Fig. 5.
Since it is postulated that parent-to-child transplants in
a family with two heterozygous parents always involves
incompatibility for one allele, the argument that this class
of transplant may be either more favourable or less
favourable needs to be considered further. This raises the
question of the relative strength of different leucocyte
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SIB-YO-SIB
Fig. 5. Hypothetical curves for three degrees of histo-
incompatibility which may be expected in sibling-to-sibling
transplants in families where both parents are hetero-
zygous for the HL-A antigens and do not posses an
antigen in common: the curves in broken lines represent
the observations in Fig. 2.
antigens. There is some serological, experimental and cli-
nical evidence to suggest that certain antigens are stronger
than others.H • n .",3l.35 More important perhaps is the histo-
compatibility function of the total number of incompatible
antigens.
Since the HL-A antigens are determined at two sub-loci
at least, each individual must possess 2 - 4 differing anti-
gens. If each parent possesses 4 different antigens and none
are shared, then every parent-to-child transplant in the
family will involve incompatibility for 2 antigens. Where
the two parents have one antigen in common, a propor-
tion of the parent-to-child transplants will involve only a
ingle incompatible antigen (Fig. 6). Other variations on
thi theme will occur if the parents have more than one
antigen, or even haplotypes in common. The different in-
fluence exerted by one-antigen incompatibility or two-
antigen incompatibilities in parent-to-child transplants
may explain the improved clinical results of the apparent-
ly better matched parent-to-child transplants in the series
reported by Singal et a/. H The fact that a high statistical
correlation was not obtained is not surprising in view of
the fact that antisera recognizing only 5 leucocyte groups
(antigen) were used in this analysis; it is evident that such
a limited range of antisera will, in a significant propor-
tion of instances, fail to distinguish the subtle degrees of
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TABLE XVII. VARJOUS DEGREES OF LEUCOCYTE ANTIGEN MATCHING
WHICH MAY BE FOUND IN RANDOM SIBLING TRANSPLANTS IN A FAMILY
WHERE THE PARE!'oITS HAVE ONE ANTIGE I COMMO OUT OF 8
AJ'o.'TIGENS DETERMINED OR TWO SUB-LOCI
identity even in parent-to-child tran plant. The fact that
uch parent-child pairs have been found in a series of
tran plants'· implies, in turn, that two genetically un-
related individuals, such as parent usually are, mu t have
an allele in common. The important deduction which fol-
low from thi observation has been tressed by Van
Thi type of immunogenetic analy is make it
obvious also that ubtle ariations in the degree
of incompatibility may occur in sibling-to- ibling
tran plants. While it remain true that incompati-
bility involve one allele in 25°~ and 2 alleles in
50°1, of ibling tran plants, the number of in-
compatible antigen may vary from one to a
maximum of 4. The degree of incompatibility
which may occur in random sibling tran plant,
where the two parents have one antigen in com-
mon, is hown in Table X lI.
lt becomes clear that un le an extensive range
of anti era of sufficiently narrow specificity is used
to type donor and recipients, it is not possible to
determine with a high degree of accuracy the
number of incompatible antigens, even in sibling-
to-sibling transplants. In such inadequate circum-
stances it is not possible to obtain a clear correla-
tion between leucocyte antigen matching and clinic-
al results. On the other hand, when adequate
serological investigation i po sible, clear correlation
becomes evident. This ha been shown by Ki s-
meyer- ielsen's experience that prospective typing
of parents and children combined with genetic
analysis makes it po sible to obtain absolutely
certain match grades for the HL-A system in
certain families, without potential incompatibilities
for undetermined antigens.'o In 13 such instances
where donors and recipient were pre-operatively
classified as identical, or incompatible for one
antigen only, the recipient were all in good clinical
ranks; whereas 4 recipient whose donors were
prospectively classed as incompatible for two
antigens, were all in inferior clinical ranks (Table
XVI).
Members of a family may be incompatible to a varying
degree and the situation within a single family is deter-
mined by the degree to which the haplotypes of the two
parents are similar. Indeed, if the father and mother have
a haplotype in common, i.e. an identical chromosome
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TABLE XVIII. CORRELATION BETWEEN DEGREE OF LEUCOCYTE MATCHING AND CLINICAL STATUS, I 64 RECIPIE TS OF 66 TRANSPLANTS \VITH
DIFFERE T GENETIC CLASSES OF DONORS (AFTER KISSMEYER- IELSEN et al.)'"
Clinical ranksSib Parent
to 10 Other Unre-
Grade ofmatching sib child related lated
A: Identical antigens .. 11 2 I
B: o antigens D + R - 4 I I
C: One antigen D + R - 3 14 3
D: Two antigen D + R - 6 7 4




















Fig. 6. The different degrees of histocompatibility which
may be found in parent-to-child transplants depending on
whether the parents have one antigen in common out of
8 antigens determined at two sub-loci. The ringed antigens
will be incompatible in parent-child transplants indicated
by an arrow.
Rood: that in the general population there must be un-
related individuals with the same two alleles. Tbis means
that identity could be obtained in unrelated donor
(cadaver donor) transplants.
In none of the series of transplants reported to date
have the leucocyte antigen determinations been pene-
trating enough to allow all the relevant antigens to be
identified. If 3 antigens can be identified without question
for any given individual, the question remains open as
to whether the individual is homozygous for one of the
3 antigens (i.e. this antigen occurs twice at one of the
sub-loci), or whether the individual possesses an antigen
for which an antiserum is not yet available. It has fre-
quently been pointed out that in related donor transplants
identity for most of the detectable antigen would imply





































TABLE XX. CORRELATION BETWEEN LEUCOCYTE ANTIGEN MATCHING
AND CUNlCAL STATUS AS JUDGED BY REJECTION EPISODES (AFTER
MORRIS et al.)"
TABLE XIX. CORRELATIO, BETWEE LEUCOCYTE GROUP MATCHING
(DIFFERENCE FROM D TO R AND R TO D ARE EQUAL) FOR 9 ANTlGE S,
AND GRAFT SURVIVAL FOR ONE YEAR (UNRELATED DONOR-RECfPtE T
PAIRS) (AFTER VA ROOD et al.)18
detectable. This argument does not apply to unrelated,
cadaver transplants. It is therefore understandable that the
correlation between leucocyte antigen typing and the clini-
cal results of transplantation are not nearly as clear in the
case of unrelated donor transplants as has been the case
in the majority of reports on related donor transplants.
It must be emphasized, however, that the smaller the
number of antigens of narrow specificity which are identi-
fied, the bigger the 'grey area' of unpredictable or in-
explicable clinical results becomes. This is well illustratt:d
by comparing the data of Kissmeyer- ielsen in Tables
XVI and XVIIl. Even related donor-recipient pairs have
to be adequately typed and matched with the recipient on
the basis of a formal genetic analysis in terms of the two
sub-loci of the HL-A system, to ensure excellence of trans-
plantation results.
During the past 2 years there have been several reports
that the re uJts obtained with cadaver kidney transplants
are definitely influenced by leucocyte antigen matching.
Van Rood et al." found that the proportion of grafts
surviving for one year is statistically correlated with the
number of HL-A antigens differing between donor and re-
cipient (Table XIX). Morris et al." reported that the clini-
cal status of the recipient as well as the early histology of




transplants (Table XX). Similar conclusions were reached
in an analysis of a large series of unrelated donor trans-
plants by Patel et al." and for a further series of cadaver






with one antigen in
cOl1l11On:
half of parent-to-child transplants
are incompatible at one sub-locus
PARENT
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TABLE XXI. CORRELATION BETWEE LEUCOCYTE A TIGE MATCHING
ACCORDING TO VAN ROOD A D CLINICAL CONDITION OF RECIPIENTS
I A SMALL SERIES OF CADAVER DO OR TRANSPLANTS (CAPE TOWN)
perience with a small serie of 10 unrelated donor trans-
plants has been similar: there is a distinct trend for the
fewer number of mismatched antigens to be a sociated
with better clinical condition of the recipient, and vice
versa. We have, however, also found evidence of a grey
area in which apparently mismatched grafts are associated
with a good clinical result (Table XXI).
CLl ICAL PROBLEMS
To place our current knowledge of tis ue typing in its
proper perspective within the field of present-day clinical
transplantation, it is necessary to provide an answer to
several recurring questions.
Why is Identity Important in Matching?
At an early stage of modern transplantation, Medawar"
underlined the principle of avoiding transplantation of an
antigen present in the donor but lacking in the recipient.
This concept carries an immunological implication which
is easily understood by most, and is therefore generalJy
accepted in principle even if it is not equally generally
applied in surgical practice. There are many, however,
who have difficulty in understanding why it may be very
undesirable in certain circumstances to transplant in the
reverse situation, i.e. where the donor lacks an antigen
which is present in the recipient. Too often this situation
i ignored on the grounds that a missing antigen cannot
possibly produce an antibody.
It has previously been stated by Walford" that while
some significant antigens remain undetected, transplanta-
tion from a negative donor to a positive recipient is not
permissible; and Dausset et al.",33 stated that wherea
identity (where donor and recipient are both positive or
are both negative) still permits incompatibility for one
unknown antigen, lack of identity (this includes a negative
donor and a positive recipient) permits incompatibility
for two undetected antigens. We have found it useful on
several occa ions to illustrate the immunogenetic argu-
ment by reference to a theoretical antigen Xa for which
no serologically detectable alJele bave been found; but in
our hypothetical situation two bitherto undetected alJeles
Xb and Xc are po tulated. Table XXll bows the situa-
tion when donor and recipient are identical, either both
positive for Xa, or both negative. Four out of 9 po sible
donor-recipient combination will be incompatible for one
of the undetected alleles. In contra t, where the donor i
negative and the recipient po itive for Xa, 7 of the 9 possi-
ble transpiants will involve incompatibility for one of the
two undetected alJeles; and now incompatibilty for both
of these antigens may occur in one instance. There is an
additional theoretical objection to transplanting from
negative to positive, which to our knowledge ba not been
considered previously. It is possible that a double dose of
inc(}"'l1patible antigen has more serious implications for the
survival of the graft than a single dose. As an example
may be taken the difference of tran planting to an Xa Xc
recipient from an Xb Xb donor or an Xb Xc donor. In
both instances the incompatible antigen i Xb, but in the
first transplant the recipient may receive twice the amount.
We do not know of any evidence to suggest that leuco-
cyte antigens have a double-dose effect in buman organ
transplantation; however, we nave no evidence to the con-
trary. Perhaps it should be noted that the incompatibilitie
which may occur for undetected antigens in our theoretical
model, where transplantation is from negative donor to
positive recipient, will in the majority of instances be
associated with a double dose of the incompatible antigens.
In an excellent example of ophi ticated immunogenetic
reasoning, Walford31 used the LA series of antigens of
Payne et al." to illustrate his argument that it is undesirable
to transplant from negative to positive. At the time, 3
alleles of this serie were detectable, i.e. LA I, LA2 and
LA3. It was known from population studies that at least
one additional allele had to exist, and the antigen LA4
was postulated. From the population statistics at his dis-
posal, Walford could calculate how often the postulated
antigen LA4 would occur as an incompatibility when the
donor was compatible (i.e. lacked the antigen) but not
identical for the known antigens LA I, LA2, LA3. In the
case of 3 phenotype the probability of apparently com-
patible types being incompatible was over 50%. Walford's
example has the particular merit in that the theoretical

















TABLE XXIT. THE POSSfBLE SIGNIFICANCE OF !DE T1TY AND NON-IDE TICAL COMPATfBILITY FOR A THEORETICAL Al'.'TIGE a WITHOUT DETECTABLE
ALLELES, BUT WITH POSTUlATED ALLELES xb AND xc
Detected phenotypes
Possible Potential Incompatible Maximum
Donor Recipient genotypes incompatibilities combinations incompatibilities
Xa+ Xa+ (i) Xa Xa (ii) to (i), (iii) 4/9 One antigen
(ii) Xa Xb (iii) to (i), (ii)
(iii) Xa Xc
Xa- Xa- (iv) Xb Xb (iv) to (v) 4/9 One antigen
(v) Xc Xc (v) to (iv)
(vi) Xb Xc (vi) to (iv), (v)
Xa- Xa+ Donor (iv), (v) or (vi) (iv) to (i), (iii) 7/9 Two antigens
Recipient (i), (ii) or (iii) (v) to (i), (ii) (vi) to (i)
(vi) to (i), (ii), (iii)
6
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anti-7b +ve anti-7b +ve
anti-HL-AS +ve anti-HL-AS _Ye
Fig. 7. Leucocyte typing sera of broad specificity, such as
leuco-agglutinating anti-7b sera, may fail to demonstrate
incompatibility for an included or frequently associated
antigen, uch as HL-A5.
Why do Some Poorly-Matched Recipients do Well
Clinically?
In the absence of other complications, the outcome of
renal transplantation depends on the balance between
immunosuppression and rejection, Many factors other
than good leucocyte antigen matching between donor and
recipient may produce a favourable balance, Patients who
are or have recently been uraemic have a reduced capacity
for immunological response'" Individual variation in com-
pensatory immunological phenomena such as acquired
tolerance or adaptation may enable a proportion of re-
cipients to carry a relatively greater load of histo-incom-





















"The antigen 7b includes the antigen HL-AS" - van Rood
Very recently Van Rood stated that the antigen 5 of
Dausset is included in antigen 7b." This would mean that
leucocytes which are Dausset-5 positive will nearly always
be 7b positive, whereas some leucocytes which are 7b posi-
tive may be Dausset-5 negative. The Dausset-5 antigen is
identical with the official antigen HL-A5.'" We have com-
pared our lymphocytotoxic 'short anti-7b' with an anti-
HL-A5 serum provided through the courtesy of the
National Institutes of Health, USA, and obtained almost
identical results. Retrospective analysis of our transplants
revealed an occasion where a donor and recipient had
both been positive with the standard leuco-agglutinating
anti-7b serum and its local agglutinating and cytotoxic
equivalents, but the recipient had been negative with the
so-called short anti-7b' (Fig. 7).
It can be seen that antisera of broad specificity, when
used by themselves, may fail to detect incompatibility for
an antigenic component which is either included in a
larger complex or which forms one of a series of frequent-
ly associated antigens. This would then explain why it is
possible for donor-recipient combinations which are ap-
parently well-matched, or even identical, in terms of












TABLE XXIII. LEUCOCYTE A T1GEN MATCHING IN A CASE OF HUMA.
HEART TRANSPLANTATION
Leuco-aggllltination antigen (Van Rood)
Donor
Recipient
Lymphocytotoxic antigens (Payne et al.)
Donor
Recipient
Iy the results of Iymphocytotoxic testing, which included
antisera for all 4 antigens of the LA series, showed that
the donor possessed LA3 and LA4, whereas the recipient
lacked both of these antigens. Therefore, compatibility
but lack of identity for the Sa antigen in a leuco-aggluti-
nation system was demonstrably associated with incom-
patibility for two undetected antigens (Table XXIII).
Why do Some Well-Matched Recipients have Poor Clinical
Results?
A small proportion of recipients who exhibit this dis-
crepancy has been noted from the earliest studies listed in
Table 1. Vredevoe et al.' ascribed this to the use of typing
era which were not sufficiently specific and therefore un-
able to detect certain antigens. Payne et al." Terasaki
et al.'·; and others have recorded similar observations
and conclusions. In general, the tatistical correlation
between closer matching and better clinical results has
become progressively stronger, the more recent the
study. This may mean that the proportion of recipients
who would be regarded as well-matched but who
exhibit rejection, is decreasing. This, in turn, is probab-
ly due to improvement in leucocyte serology.
The increasing refinement of leucocyte antigen
detection i well illustrated by recent experience with
one of our heart transplants. By the leuco-agglutina-
tion method of Van Rood the antigen 7b is a well-
defined antigen. n We have obtained locally in Cape
Town a leuco-agglutinating serum which gives virtually
identical re ults with a reference anti-7b serum
obtained from Van Rood. We have also Iymphocyto-
toxic antisera which are specific for leucocytes from
people who are 7b positive by leuco-agglutination
tests; one serum gives a pattern of positives and
negatives among random people which is almost
identical with that obtained with the reference anti-7b,
while another type of serum reacts positively only with
peo"le who are 7b po itive but with a minority of them.
The LA series of antigens have provided us with an
actual example of the dangers inherent in transplanting
negative to positive. With the exception of LA2, the anti-
gen of the LA series are detectable only by leuco-agglu-
tination methods using defibrinated blood, or by lympho-
cytotoxic techniques. This is so because the LA antibodies,
with the exception of anti-LA2, require complement for
their action; the EDTA which is incorporated in Van
Rood's leuco-agglutination method renders complement
ineffective, so that only the equivalent of LA2, i.e. the
antigen Sa, is detected in Van Rood's system."'''' In one of
our transplants the donor was negative and the recipient
positive for Sa. The transplant operation was undertaken
on the basis of the leuco-agglutination results. Sub equent-
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TABLE XXV. LEUCOCYTE TYPING RESULTS WHERE THE DONOR MAY BE
POSITIVE AND THE RECIPIENT NEGATIVE, WITHOUT IMPLICATION OF
INCOMPATIBILITY FOR A COMPLETE MAJOR ANTIGEN
proportion of such persons. The last two sera represent
reagents of narrower specificity.
Table XXV illustrates how the use of a single serum
for a particular antigenic pecificity may provide mislead-
ing results. If the anti-4a serum CT17 had been used alone
to type leucocytes from I to 24 in Table XXIV a pro-
spective donors and the leucocyte samples 25 - 27 as pro-
spective recipients, a transplant from anyone of the 24
prospective donors would have been labelled as 4a in-
compatible with all three prospective recipients. Serum
eTI7 may be a somewhat weak reagent, or it may be that
there is indeed incompatibility from donor to recipient for
a more or less minor component of the 4a antigen; how-
ever, it would be quite incorrect to c1as ify such a trans-
plant as one involving incompatibility for the major anti-
gen.
Table XXV presents the same argument which we have
advanced previously." Unless antisera are capable of de-
tecting such minor antigenic differences and placing them
in their proper perspective in relation to major com-
ponent , the matching and selection of donors and re-
cipients will not lead to clinical results which are fully
predictable. With reference to the schematic representation
(Table XXV) of donors who possess an antigenic com-
ponent which is lacking in the recipients, one may
summarize as follows: if the incompatible antigenic
determinant is sufficiently immunogenic to represent a
transplantation antigen, then the failure to detect the in-
compatibility may lead to an unexpected immunological
complication after transplantation; if the additional anti-
genic determinant is detected serologically, but does not
represent a transplantation antigen, then an apparent
incompatibility between donor and recipient may yet be
associated with transplantation which is not followed by
immunological complications.
The question may justifiably be asked, at this stage, what
the prospects are of obtaining leucocyte typing reagents of
sufficient specificity to avoid ambiguity. In our opinion
some optimism is quite justified. Many workers, among
them Kissmeyer-Nielsen, have now refined their antisera
to a stage where the majority of antigens at the two sub-
loci of the HL-A system can be accurately defined (Table
XXVI). (For this very recent information we are greatly
indebted to Or Kissmeyer-Nielsen who kindly permitted
one of his senior assistant to spend some time with us
tissue-typing reagents probably played a major part to date
in the failure to recognize some suitable donor-recipient
combinations. Again, this is failure attributable to the use
of antisera which are not sufficiently specific.
The antigen 4a of Van Rood is a relatively strong
transplantation antigen. It is well known, however, that
this is an antigen of broad specificity which probably
consists of a series of frequently associated component
antigens. lO ,19,Z7,:>1,1J Many anti-4a sera can be split up into
4 or 5 Iymphocytotoxic components by appropriate ab-
sorption with leucocytes from selected 4a-positive indivi-
duals. We have also found 'short' agglutinating anti-4a
antibodies in the sera of pregnant women. Table XXIV
shows the results obtained with leuco-agglutination tests
on random samples of 41 people from the Cape Town
TABLE XXIV. A Tr-4a SERA (CT = CAPE TOWN)
Leucocyte Van Rood CT CT CT CT
samples 4a 49 17 68 51
1 + + + + +
2 + + + +
3 + + + + +
4 + + + T J-
5 + + + + +
6 + + + , J-
7 + + + + J-
8 + + J- + ,
9 + + + ,
10 + + + + +
11 + + + +
12 + + +- , -;-
13 + + + +
14 + + + ,
15 + + + + +
16 + + , +
17 + + + +
18 + + +
19 + + + +
20 .+ + + J-
21 + + + +
22 + + + -!-
23 + + -!- +
24 + + + +
25 + + +
26 + + +















population; 27 of these people were positive with stan-
dard anti-4a sera supplied by Van Rood. Also shown are
the results of one of the locally obtained sera which are
identical with the standard serum. In addition there are
two Cape Town sera (CT17 and CT51) which are specific
in so far as they agglutinate only 4a-positive leucocytes,
but they are 'short' in so far as they react only with a
7
Anti-4a sera
Van CT CT CT
Rood 49 17 68
11024 + + + ,
25 J- +
26 + + +
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for the purpose of testing our reference panel of leucocyte
donor with his latest sera.)
TABLE XXVI. THE HLA YSTE 1 OF HUMA LYMPHOCYTE GROUPS
ACCORDING TO KISSMEYER-NIELSE '
TlI'o
sub-loci
First HLA-l, HLA-2, HLA-3, HLA-4, Ba, IL ',0-17, LI
Second HLA-5. HLA-7, HLA-8, R*,T12, H ,BB, FJH, LID, MH
We are not suggesting that the last of the missing
leucocyte antigen will be discovered within the next
months or even years. Red blood cell serology has been
pursued for nearly 70 years, and new antigen , or new
variant of old antigens, are still being discovered with
great regularity. However, the major red blood cell anti-
gens which are important in clinical blood transfusion
were all discovered at a relatively early stage. By the
same token, it will probably take a considerable time to
unravel all the immunogenetic intricacies of leucocyte
serology, but there is hope that the clinically more im-
portant antigens are being recognized for what they are
with increasing regularity in the better-equipped typing
la bora tories.
The next question may well be: what are the chances
of the more selective antisera becoming generally avail-
able for clinical application? Again, we think there is
room for optimism. Many centres are pursuing active
programme for selection or production of excellent
typing era. With the micro-droplet method which are
now becoming standard practice, even a few milWitres of
erum will sustain a very active tran plantation pro-
gramme for several years.
Our own experience has been encouraging. Over a
period of approximately 6 months the sera from 10,000
pregnant women have been screened for leucocyte anti-
bodies. Sera initially selected for leuco-agglutinating
activity were recently re-examined in terms of the Iympho-
cytotoxic antigens shown in Table XXVI. Preliminary re-
ults obtained from our computer programme indicate
that 7 of these antigens can be identified adequately.
Furthermore, it seems as if we have antisera for several
of the remaining antigens, but that these antisera possess
also some weak additional antibodies which will have to
be eliminated. This can be done either by absorption or,
possibly, by using the antiserum at a suitable dilution.
ince we have at least lOO millilitres of most of these sera
on hand, the needs for everal very active transplantation
centres for I or 2 years could be met with such a supply.
Why are Well-Matched Organs Nor Transplanted?
It i now accepted that two hi tocompatibility criteria
must be satisfied: the donor must be ABO compatible
with the recipient:'·" and the recipient must be free of
antibodies which react with donor leucocyte in direct
cross-matching tests."'" As yet there is no justification for
a dogmatic statement about the particular leucocyte anti-
gens, or the number of such antigens which preclude
organ transplantation. Experience to date indicate that
donors and recipient who are identical, or identical for
all but one of the HL-A antigen , may be regarded a
well-matched in terms of leucocyte antigens. While clinical
transplantation is in its present form, this degree of match
will be difficult to achieve for many patients; even com-
patibility for the major antigens may not be attained in
every ca e. Thi applies particularly to transplantation
other than that of the kidney. The small likelihood of
achieving well-matched unrelated donors has been well
documented both on theoretical and on practical grounds.
The alternative to an identical match is best considered
separately for related and unrelated donors.
CHOICE OF BEST DO OR
Family Donors
Whereas many leucocyte phenotypes have been ob-
served in terms of defined antigens (over 100 phenotype
with the 16 antigen detected by Daus et and Rapaport),"
a maximum of 6 genotypes (ab x cd ~ ac, ad bc and bd)
exists within a family, and among siblings only 4, so that
the chance of identity is much increased among family
members.
When the leucocyte phenotypes of both parents and
the siblings are available, genetic analy is may identify the
segregation of chromosome (i.e. clusters of antigens) in
the family. This permits one to consider the possible
existence of identity or semi-identity, and compatibility or
incompatibility for postulated allelic genes not yet detected
serologically.".".33."
Daus et and Rapaport" have suggested that in the ab-
sence of a monozygous twin, the best donor is an identical
ibling; next be t i a donor, either ibling or parent, who
carries only one chromosome (a combination of antigens)
which i absent in the recipient, i.e. donor and recipient
are semi-identical. The decision which of the two chromo-
omes that differ i less disadvantageou must be based
on antigen number, strength and association. With equal
degree of incompatibility, siblings are preferred to parents,
since they are more likely to be identical for postulated
but as yet undetectable antigen in the HL-A and other
histocompatibility systems. If there are no semi-identical
sibling, the parent with the better allele should be the
third choice. Fourthly, siblings who are not semi-identical
will be better than a non-related donor who presents an
equal degree of incompatibility-again in view of the
greater likelihood of identity for undetected antigens.
Unrelated Donors
Dau set et al." have calculated the chance of a prospec-
tive donor, or an available donor organ, being identically
matched for the 5 major histocompatibility antigens (i.e.
blood groups A and B, and leucocyte antigens I, 3 and 7)
in their population. The chances of a recipient varied from
\·1 to 100% and for an organ from 0·6 to 71'3%. Taking
into account 16 defined antigens, Dausset and Rapaport"
observed more than I00 phenotype in the population,
which reduces the probability of identity in the random
population to almo t nil. Ki smeyer- ielsen et al.'9 con-
cluded that one must calculate with 7 and 8 genes on the
two ub-Ioci respectively; this give 1,008 possible pheno-
types, without taking blood groups into account.
It has been pointed out, however, that different pheno-
types will not be eq ually di tributed in the general popu-
lation. As with the rhesus system, certain phenotypes will
be relatively common and offer a proportionately better
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chance of being well matched.""" Dausset has also pointed
out that thousands of phenotypes exist for the red cell
antigen, but that for the great majority of blood trans-
fusions only 3 are considered, i.e. A, B and Rh positive
(Rho and D). Van Rood has referred to the observation
that certain rhesus alleles are less prone to provoke anti-
bodies and suggests that this may be the case also with
ome leucocyte antigen haplotypes.'"
Dausset and Rapaport" state that in the absence of an
identical unrelated donor, it may be difficult to decide what
is least incompatible. It is suggested that the least number
of detectable incompatible antigen (0 + to R -) be select-
ed, even if it is accepted that detectable reverse mismatches
(0 - to R +) may imply donor-to-recipient incompatibility.
As a minimum, it should be the aim to achieve donor-
recipient identity for the key antigens of each series of
closely associated antigens (Dausset's I, 3 and 7 which are
equal or approximately equivalent to HL-A2, 4 and 6),
on the assumption that this implies identity for known
and unknown associated antigens.
Van Rood et al." also suggested that for unrelated (cada-
ver) donor transplants one should concentrate on the main
leucocyte antigens. In their leuco-agglutination system
thi implies 9 groups. With a reasonably large pool of re-
cipients, their policy is: if an identical donor-recipient
combination is not available, a combination mismatched
for one or two antigens-and very exceptionally for 3
antigens-is accepted. It wa previously shown that the e
9 antigens, as distributed among 333 randomly selected
per ons, would produce 2 incompatibilities (donor positive
and recipient negative) as the commonest situation in
random matches; and that 3 incompatibilities with mis-
matches must be expected in nearly 17% of transplants.
The average number of total mismatches (incompatibilities
+ reverse mismatches) would be between 3 and 4 in a
large series of random selections."
Summarizing their more recent experience, Terasaki
et al.'" reported that from a pool of 30 recipients on dia-
lysis, the effective pool for a given cadaver organ was
often reduced to between 4 and 8 by ABO incompatibility
and clinical unsuitability at the given time. In spite of
prospective typing, the policy of using all cadaver kidneys
resulted in a large proportion of mismatched transplants.
Furthermore, transplantation to those recipients in the
pool who had phenotypes which were easier to match,
created a collection of long-waiting recipient with pheno-
types which had a lesser probability of beiflg matched.
Con equently the proportion of mismatched transplants
increased progressively.
The experience which has been re iewed here, and
considerations and arguments arising therefrom, have
been largely concerned with kidney tran plantation and
experimental skin grafts. Other organs require a somewhat
different approach as regards prospective typing and selec-
tion of the donor.
ELECTIO OF DO ORS FOR TRA SPLA TATIO OF SINGLE
ORGAN
In contrast to the prospective kidney recipient, patient
requiring heart, Jiver or other visceral transplants are
often too ill to wait an indefinite period and cannot be
sustained by treatment equivalent to dialysis. Furthermore,
this relatively urgent transplantation is entirely dependent
on unrelated (cadaver) transplants. Altogether, the op-
portunity of finding a well-matched organ is less than in
the ca e of a kidney.
The Cape Town experience with 5 heart transplant
offers an illustration of the problems which are en-
countered in clinical practice. Table XXVII shows the
ABO compatibility and the leucocyte antigen matching
according to Van Rood; also shown are the m21tching
grade ymbols used by Terasaki. The tis ue typing methods
of Van Rood and of Tera aki are not strictly comparable,
since each technique detects certain antigens not recog-
nized by the other. 17." evertheles, it wa considered
worth while to convert the data obtained from Van Rood'
method to the nomenclature of Tera aki. in order to com-
pare our results with a larger series of heart transplant
from Houston. For this purpose, the comparison contained
in Table XXVIII was used. In determining the match
grade according to Terasaki, the leuco-agglutination anti-
gens 6a, 6b and 7a were ignored when these were present
as incompatibilities. Van Rood ha stated that the antigen
6a is a weak one, and has expressed some doubt
whether 6b is a very distinct antigen; it is said that the
recognition of the 7a antigen has never been quite satis-
factory. On the other hand, the 3 antigens of Terasaki
which do not have equivalents in Van Rood's system, i.e.
], 8 and 4, are considered to be transplantation antigens.
To accommodate these 3 antigens in arriving at a matching
TABLE XXVII. DEGREE OF LEUCOCYTE ANTIGEN MATCHING IN 5 HEART TRANSPLANT OPERATIONS (CAPE TOWN)
Illcompatible Reverse
allfigells: mismatches: Tellfati!'e
4 6 7 0.0/11011- dOllor ...Lve donor -l'e gradillg Survil'Ol
idemical recipiellf recipiellf a/ter ill
ABO a b a b a b c d a allfigells -l'e -l'e Terasaki days
J. Donor 0 T
Recipient A , 2 6a a B I
(died)
2. Donor 0
Recipient B 2 4a,6b C >582
3. Donor 0 ...L
Recipient A -'- 3 4a 4b,6b C >333
4. Don@r 0 ...L
Recipient 0 ...L 4 6b, 7c 4a, 7d C 64
(died)
5. Donor 0 ...L ~
Recipient B + ...L 3 6a 7c, 8a D >111
8
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TABLE XXVIII. COMPARISO MATCHI G OMENCLATURE
Payne et al.SI
'Antigen 6a is apparently a weak one ... It is, however, also possible that the 6a
antigen is almost always present and the 6b antigen is super.imposed on it. The
antigen 6b is significantly associated with the antigen 7c. The recognition of the 7a
antigen has never been Quite satisfactory: (Van Rood)
grade according to the scheme of Terasaki, we have used
the results which we obtained with antisera of the speci-
ficity LA I, LA3 and LA4. The last 3 antigens as described
originally by Payne et al. are the equivalents to Terasaki's
I, 8 and 4 (Table XXVIII), and are regarded as histo-
compatibility antigens.""'" The fifth transplant was al-
located a grade D match on the two additional incompati-
bilities detected by Iymphocytotoxic tests (Table XXUD.
Terasaki Mean days
typing Living Days of ofsurvival
grades patiellls survival Dead at death
A
B 1 > 88 0
C+ ] >]72 0
C 4 > ]]O(mean) 4 82
C- l > 130 4 57
D 1 > 53 5 53
F
TABLE XXX. CORRELATlO BETWEE' GRADES OF LEUCOCYTE ANTIGEN
MATCHING A rn SURVIVAL OF HEART TRA SPLANT PAT[E/','TS rN
HOUSTON (AFTER TRENTON)S8
the patients' best interests to accept a lesser degree of
compatibility.
The degree of mismatch which was accepted must be
judged on the function of the graft or on survival. Two
of the recipients in this small series have died from the
complications of immunosuppression; the number of non-
identical antigens were 2 and 4 respectively. Two long-
term survivors (582 and 333 days respectively) represent
2 and 3 non-identical antigens respectively; the third sur-
vivor who presents with less satisfactory graft function
has survived for III days with 3 non-identical antigens.
These observations may be compared with Van Rood's
analysis of kidney graft survival for one year (Table XIX).
Sixty per cent of donor-recipient pairs with 2 - 3 HL-A
antigens differing survived this period, whereas 4 or more
differing antigens were associated with only 30% survival.
In the terms used by Terasaki the two patients who died
had grade Band C matches respectively; the two long-
term survivors both have grade C matches, while the re-
cipient with the shortest survival and who has presented
ome serious problems in clinical management represents
a grade D match. These latter observations can be com-
pared with those presented by TrentonSS (Table XXX) in
respect of 17 heart transplant recipients who had been
typed retrospectively by Terasaki or prospectively accord-
ing to Terasaki. On the basis of the Houston data we feel
that grade C is the significant level of match in heart
transplantation; lesser grades of match were associated
with less than 50% urvival at about 130 days.
(6) 5 11 2 8 4
LA2 LA I LA3 LA4




It is clear that our predetermined level of desirability,"
i.e. identity or near identity for Van Rood's leucocyte
antigens, was not obtained in any of the 5 transplants. This
was due mainly to clinical con iderations, because all these
patients were at or near terminal stages of myocardial
failure. As each of these patients was accepted as a pro-
spective recipient on clinical grounds, the leucocyte anti-
gen patterns were determined for the purposes of donor
matching. In each instance it was realized that the indi-
vidual leucocyte phenotype of the prospective recipients
did not provide a reasonable probability of obtaining an
identical or near-identical donor.
The probability of finding an acceptable match for these
5 recipient phenotypes could be calculated on the basis of
the known ABO blood-group distribution among the
several population groups of Cape Town, in conjunction
with the di tribution of leucocyte antigen phenotypes in a
large series of randomly selected White and non-White
per ons in this area. The probabilities of achieving ABO
compatibility and various grades of leucocyte antigen
matching are shown in Table XXIX.
TABLE XXIX. APPROXIMATE PROBABILITIES OF ABO COMPATIBILITY AND
DIFFERENT DEGREES OF LEUCOCYTE ANTIGEN MATCHrNG FOR 5 HEART
TRANSPLANT RECIPIENTS (CAPE TOWN)-
ABO
Total number of leucocyte compati-
ABO antigens mismatched in bility plus
com- terms of Van Rood leucocyte
Reci- pari- identity
pielll hility Nil One Two Three or near
1 ·78 0 0 ·04 . ]2 0-0
2 '56 ·0] ·07 ·26 ·5 0·04
3 ·78 0 ·03 ·32 ·73 0·02
4 -39 0 ·05 ·25 ·53 0·02
5 ·56 0 ·11 ·20 -41 0·06
°The probability of ABO compatibility further reduces the probability of the
leucocyte rAatching.
The over-all probability of obtaining ABO compati-
bility plus identity or near identity for the 9 leucocyte
antigens of Van Rood's system were, for the 5 prospective
heart recipients respectively: nil, 4%, 2%, 2% and 6%. In
view of these patients' deteriorating condition and the
hortage of prospective donors, it was considered to be in
From the combined but still limited observations avail-
able at present, it would appear that 2 - 3 non-identical
antigens of Van Rood's group 4 system, or -a grade C
match, is acceptable in human heart transplantation, with
the best of present-day methods of immunosuppression.
This grade of match is better than would be obtained, on
the average, in random unselected cadaver transplants.
Therefore, even while the present shortage of prospective
donors lasts, and heart transplantation is offered only to
patients in the terminal stages of their disease, leucocyte
typing has something to offer. It should be possible in the
majority of instances to select better than the average
achieved by chance, and to avoid altogether the gross mis-
matches which occur in a proportion of unselected trans-
plants.
SUMMARY
Recent studies which established the correlation between
leucocyte group matching of kidney donors and recipients.
and the outcome of the transplantation, are reviewed. Some
of the serological problems which are still inherent in leucocyte
antigen typing are considered in detail. Experience with leuco-
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cyte typing in heart transplanta~on is .b~efiy rec~rded. It is
concluded that even for prospectIve recipients of smgle o~gan
transplants, who cannot wait indefinitely, leucocyte. a~tJgen
matching offers a better than random chance of achlevlDg a
reasonable match and therefore the probability of an im-
proved clinical result.
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The author of this slim but instructive volume was until re-
cently the Director General of the ational Board of Health
of Sweden, and is an authority on social medicine. He clearly
indicates the necessity for studying change in a community
which affect health, in planning comprehensive health services
for that society. Effective statistical records are an essential
component of intelligent planning and in Sweden such record
have been highly developed and include, among many others,
a cancer register, a malformations register and the monitoring
of adverse effects of drugs (not limited to abuse or dependence
producing drugs). The development of the Swedish regionalized
hospital and health systems is discussed.
This is a book which should be read by all medical pra -
titioners, not only those specializing in social medicine.
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